Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Nov 2020
Historique:
received: 28 05 2020
revised: 13 07 2020
accepted: 14 07 2020
pubmed: 17 8 2020
medline: 20 4 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

To study the antikinetoplastid 3-nitroimidazo[1,2-a]pyridine pharmacophore, a structure-activity relationship study was conducted through the synthesis of 26 original derivatives and their in vitro evaluation on both Leishmania spp and Trypanosoma brucei brucei. This SAR study showed that the antitrypanosomal pharmacophore was less restrictive than the antileishmanial one and highlighted positions 2, 6 and 8 of the imidazopyridine ring as key modulation points. None of the synthesized compounds allowed improvement in antileishmanial activity, compared to previous hit molecules in the series. Nevertheless, compound 8, the best antitrypanosomal molecule in this series (EC

Identifiants

pubmed: 32795774
pii: S0223-5234(20)30640-1
doi: 10.1016/j.ejmech.2020.112668
pii:
doi:

Substances chimiques

Imidazoles 0
Pyridines 0
Serum Albumin 0
Trypanocidal Agents 0
imidazopyridine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112668

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Cyril Fersing (C)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Clotilde Boudot (C)

Université de Limoges, UMR Inserm 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 Rue Du Dr Marcland, 87025, Limoges, France.

Romain Paoli-Lombardo (R)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Nicolas Primas (N)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Emilie Pinault (E)

Université de Limoges, BISCEm, US 042 INSERM - UMS 2015 CNRS, Mass Spectrometry Platform, CBRS, 2 Rue Du Pr. Descottes, F-87025, Limoges, France.

Sébastien Hutter (S)

Aix Marseille Univ, IHU Méditerranée Infection, UMR VITROME - Tropical Eukaryotic Pathogens, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.

Caroline Castera-Ducros (C)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Youssef Kabri (Y)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Julien Pedron (J)

LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France.

Sandra Bourgeade-Delmas (S)

UMR 152 PHARMA-DEV, Université de Toulouse, IRD, UPS, Toulouse, France.

Alix Sournia-Saquet (A)

LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France.

Jean-Luc Stigliani (JL)

LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France.

Alexis Valentin (A)

UMR 152 PHARMA-DEV, Université de Toulouse, IRD, UPS, Toulouse, France.

Amaya Azqueta (A)

Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, C/ Irunlarrea 1, CP 31008, Pamplona, Navarra, Spain.

Damián Muruzabal (D)

Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, C/ Irunlarrea 1, CP 31008, Pamplona, Navarra, Spain.

Alexandre Destere (A)

Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France; INSERM, UMR 1248, University of Limoges, France.

Susan Wyllie (S)

University of Dundee, School of Life Sciences, Division of Biological Chemistry and Drug Discovery, Dow Street, Dundee DD1 5EH, Scotland, United Kingdom.

Alan H Fairlamb (AH)

University of Dundee, School of Life Sciences, Division of Biological Chemistry and Drug Discovery, Dow Street, Dundee DD1 5EH, Scotland, United Kingdom.

Sophie Corvaisier (S)

Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Marc Since (M)

Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Aurélie Malzert-Fréon (A)

Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Carole Di Giorgio (C)

Institut Méditerranéen de Biodiversité et D'Ecologie Marine et Continentale (IMBE), Aix-Marseille Université, UMR CNRS IRD Avignon Université, Campus Timone - Faculté de Pharmacie, 27 Boulevard Jean-Moulin, F13385, Marseille Cedex 05, France.

Pascal Rathelot (P)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Nadine Azas (N)

Aix Marseille Univ, IHU Méditerranée Infection, UMR VITROME - Tropical Eukaryotic Pathogens, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.

Bertrand Courtioux (B)

Université de Limoges, UMR Inserm 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 Rue Du Dr Marcland, 87025, Limoges, France.

Patrice Vanelle (P)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin, CS30064, 13385, Marseille Cedex 05, France.

Pierre Verhaeghe (P)

LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France. Electronic address: pierre.verhaeghe@lcc-toulouse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH